Narrative review explores CSF1R inhibitor potential in pediatric medulloblastoma precision immunotherapy

This narrative review focuses on the potential of CSF1R inhibitors within the context of precision immunotherapy for pediatric patients with medulloblastoma. The scope of the discussion centers on tailoring immunotherapeutic approaches to specific molecular subtypes, including WNT, SHH, Group 3, and Group 4. The authors emphasize that characterizing the immune microenvironment’s heterogeneity across these subtypes is a fundamental step toward improving patient outcomes in this high-risk population.

The authors synthesize the theoretical rationale for targeting CSF1R, suggesting that such interventions could modulate the tumor immune landscape. However, the review does not report pooled effect sizes, specific sample sizes, or comparative data against standard therapies. Consequently, no quantitative estimates of clinical benefit or specific adverse event profiles are provided within this text.

Significant limitations are acknowledged by the absence of reported primary outcomes, secondary outcomes, and detailed safety information. The setting of the proposed interventions and the specific patient cohorts are not detailed. Therefore, the practice relevance remains conceptual, highlighting the need for further research to validate these strategies before they can be integrated into standard care for pediatric medulloblastoma.